Abbreviations
KU Leuven is one of Europe’s oldest universities, which consistently ranks amongst the world’s best universities and is widely regarded as one of the most innovative research institutions.
The KU Leuven Institute for Single Cell Omics (LISCO) nucleates interdisciplinary expertise in single-cell and spatial multi-omics to investigate normal development, aging and disease processes in humans and other organisms, down to the biology of unicellular life forms. LISCO aims to develop innovative single-cell analysis technologies and high-throughput platforms to enable breakthrough biomedical and biological science that transcends an individual research lab, to pioneer and set standards in disruptive single-cell technologies and research, and to translate technologies and biomedical discoveries to the clinic. It unites researchers from over 55 groups from KUL, UZ Leuven and VIB-KU Leuven, creating a framework for academic and industrial collaboration, service provision, and training of the next-generation researchers.
The Laboratory of Cell Stress & Immunity (CSI) is embedded within the Department of Cellular & Molecular Medicine (CMM), in KU Leuven (Belgium). The CSI laboratory is headed by Prof. Abhishek D. Garg and focuses on the following research themes: cancer immunology & immunotherapy, immunology of cellular stress & immunity cycle, computational immunology and multi-omics, single cell and spatial mapping in immuno-oncology. Ultimately, the CSI lab aims to specialise in reverse translational approaches to hasten progress in immuno-oncology and help improve the therapeutic outlook for cancer patients, in close collaboration with leading researchers, immunologists, and oncologists, in Belgium and abroad.
UZL is one of the participating organisations on behalf of KUL. UZL is the largest Belgian University Hospital and has a comprehensive multidisciplinary neuro-oncology team and works together with the Leuven Cancer Institute and Brain Tumor Focus Group and the Leuven Brain Institute.
What is KUL-LISCO’s main role?
Project coordination and innovation management
Providing expertise in brain tumour biology, spatial single-cell profiling & imaging
Using multiome approaches, including spatial transcriptomics and proteomics
Collection of retrospective data from cohorts
Mapping of the tumour-host/immune microenvironment
Which work packages is KUL-LISCO involved in?
See our dedicated page for more details on the GLIOMATCH work plan.
KUL-LISCO leads work packages 2 and 3 and contributes to work packages 1, 7 and 8
See the detailed project work plan here.
What is KUL-CMM’s main role?
Data management and immunological interpretation of spatial cellular communities and their inter-cellular interactions in glioblastoma patients
Interfacing with radiomics analyses and overall patient clinico-pathological parameters
Which work packages is KUL-CMM involved in?
See our dedicated page for more details on the GLIOMATCH work plan.
KUL-CMM leads work package 1 and contributes to work packages 3, 4, 7 and 8
What is KUL-UZL’s main role?
Running the retrospective clinical trial to feed a data lake on GBM patients treated with immunotherapy approaches
Running a small scale proof-of-concept phase 0 clinical trial on anti-Gal1-siRNA formulations via transnasal delivery route in the context of DC-based vaccination strategy
Which work packages is KUL-UZL involved in?
See our dedicated page for more details on the GLIOMATCH work plan.
KUL-UZL contributes to work packages 2, 5, 7 and 8
Who represents KUL-LISCO?
Who represents KUL-CMM?
Who represents KUL-UZL?
GLIOMATCH Partners
GLIOMATCH Partners
